TriSalus Life Sciences
TLSI· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +39.3% in FY2025
Mary Szela is the CEO of TriSalus Life Sciences and was paid $4.8M in FY2025 (Dec), up 17%.
Pay$100 in the stock at the end of FY21 → $71
Executives3
See all- 1Mary SzelaCEO and PresidentFY2025
- 2David PatienceChief Financial Officer(*)FY2025
- 3Richard MarshakChief Commercial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTriSalus Life Sciences paid its 3 named executives $9.8M in total in FY2025 (Dec). CEO Mary Szela was paid $4.8M of that.
| Name | |||
|---|---|---|---|
| Mary SzelaCEO and President | |||
| David PatienceChief Financial Officer(*) | Not disclosed | ||
| Richard MarshakChief Commercial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for TriSalus Life Sciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 31, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Apr 15, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jul 19, 2024 | FY2023 |
| Annual report | 10-K | Apr 11, 2024 | FY2023 |
